Ctrl K
SLS trades 150.7% below Wall Street's consensus target of $35.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes SLS achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 5 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 9, 2026, SELLAS Life Sciences Group, Inc. (SLS) has a Wall Street consensus price target of $35.00, based on estimates from 5 covering analysts. With the stock currently trading at $13.96, this represents a potential upside of +150.7%. The company has a market capitalization of $2.60B.
Analyst price targets range from a low of $35.00 to a high of $35.00, representing a 0% spread in expectations. The median target of $35.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 5 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, SLS trades at a trailing P/E of -55.8x. Analysts expect EPS to grow -19.5% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 IMVTImmunovant, Inc. | $8.2B | $39.57 | $40.00 | +1.1% | Buy | — | 23 |
 ADMAADMA Biologics, Inc. | $2.2B | $9.54 | $18.67 | +95.7% | Buy | 12.0x | 10 |
 NKTRNektar Therapeutics | $2.5B | $75.44 | $150.00 | +98.8% | Buy | — | 33 |
 CLDXCelldex Therapeutics, Inc. | $2.6B | $39.12 | $62.63 | +60.1% | Buy | — | 19 |
 AGENAgenus Inc. | $309M | $7.43 | $25.00 | +236.5% | Buy | 9.6x | 11 |
 HALOHalozyme Therapeutics, Inc. | $12.8B | $108.31 | $103.00 | -4.9% | Buy | 12.9x | 27 |
 NVAXNovavax, Inc. | $1.7B | $10.19 | $18.00 | +76.6% | Buy | — | 23 |
 IOVAIovance Biotherapeutics, Inc. | $3.9B | $8.70 | $7.83 | -10.0% | Buy | — | 21 |
 NUVLNuvalent, Inc. | $9.1B | $123.96 | $127.32 | +2.7% | Hold | — | 19 |
 FATEFate Therapeutics, Inc. | $291M | $2.50 | $5.63 | +125.2% | Buy | — | 31 |
Quick answers to the most common questions about buying SLS stock.
The consensus Wall Street price target for SLS is $35, representing 150.7% upside from the current price of $13.96. With 5 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
SLS has a consensus rating of "Buy" based on 5 Wall Street analysts. The rating breakdown is predominantly bullish, with 5 Buy/Strong Buy ratings. The consensus 12-month price target of $35 implies 150.7% upside from current levels.
SLS's current price is $13.96 with a consensus target of $35 (150.7% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $35 for SLS, while the most conservative target is $35. The consensus of $35 represents the median expectation. These targets typically reflect 12-month expectations.
SLS is moderately covered, with 5 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month SLS stock forecast based on 5 Wall Street analysts shows a consensus price target of $35, with estimates ranging from $35 (bear case) to $35 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on SLS, with a "Buy" consensus rating and $35 price target (150.7% upside). 5 of 5 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
SLS analyst price targets range from $35 to $35, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $35 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.